Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe

被引：28
|
作者：
Reinert, Ralf R. [1 ]
Paradiso, Peter [2 ]
Fritzell, Bernard [1 ]
机构：
[1] Pfizer Inc, Int Sci & Clin Affairs Vaccines, Paris, France
[2] Pfizer Inc, Collegeville, PA USA
来源：
EXPERT REVIEW OF VACCINES | 2010年 / 9卷 / 03期
关键词：
PNEUMONIAE SEROTYPE 19A; ACUTE OTITIS-MEDIA; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; CHILDHOOD IMMUNIZATION; IMPACT; CHILDREN; DISEASE; POLYMORPHISMS; RESISTANCE;
D O I：
10.1586/ERV.10.6
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：229 / 236
页数：8
相关论文
共 50 条
  • [21] Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    Miller, Elizabeth
    Andrews, Nicholas J.
    Waight, Pauline A.
    Slack, Mary P. E.
    George, Robert C.
    VACCINE, 2011, 29 (49) : 9127 - 9131
  • [22] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]
    Duggan, Sean T.
    DRUGS, 2010, 70 (15) : 1973 - 1986
  • [23] Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
    Shpagina, L. A.
    Kotova, O. S.
    Shpagin, I. S.
    Loktin, E. M.
    Rukavitsyna, A. A.
    Kuznetsova, G., V
    Kamneva, N., V
    Laletina, M. A.
    TERAPEVTICHESKII ARKHIV, 2018, 90 (11) : 55 - 61
  • [24] Pneumococcal Conjugate Vaccine-elicited Antibody Persistence and Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Previously Vaccinated with 4 Doses of Either 7-Valent or 13-Valent Pneumococcal Conjugate Vaccine
    Quinet, Beatrice
    Laudat, France
    Gurtman, Alejandra
    Patterson, Scott
    Sidhu, Mohinder
    Gruber, William C.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (10) : 1065 - 1076
  • [25] Infants at Risk for Invasive Pneumococcal Disease in the 13-Valent Pneumococcal Conjugate Vaccine Era
    Yildirim, Inci
    Pelton, Stephen I.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (01) : 91 - 92
  • [26] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]
    Sean T. Duggan
    Drugs, 2010, 70 : 1973 - 1986
  • [27] Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine
    Frenck, Robert, Jr.
    Thompson, Allison
    Yeh, Sylvia H.
    London, Arnold
    Sidhu, Mohinder S.
    Patterson, Scott
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    Gurtman, Alejandra
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (12) : 1086 - 1091
  • [28] Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians
    Grant, Lindsay R.
    Hammitt, Laura L.
    O'Brien, Sarah E.
    Jacobs, Michael R.
    Donaldson, Connie
    Weatherholtz, Robert C.
    Reid, Raymond
    Santosham, Mathuram
    O'Brien, Katherine L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (08) : 907 - 914
  • [29] Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study
    Vojicic, Jelena
    Grajales, Ana Gabriela
    Cane, Alejandro
    VACCINE, 2023, 41 (27) : 3949 - 3950
  • [30] Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults
    Gladstone, Rebecca A.
    Jefferies, Johanna M.
    Faust, Saul N.
    Clarke, Stuart C.
    EXPERT REVIEW OF VACCINES, 2012, 11 (08) : 889 - 902
12345